Standard BioTools Inc. Revenue
Standard BioTools Inc. (LAB) reported Revenue of $20.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- Standard BioTools Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $20.10M, a 7.62% decline year-over-year.
- Standard BioTools Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $21.15M, a 4.57% increase year-over-year.
- Standard BioTools Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $23.80M, a 3.96% decline year-over-year.
- Standard BioTools Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $19.55M, a 11.47% decline year-over-year.
- Standard BioTools Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $85.33M, a 6.24% decline from fiscal 2024.
- Standard BioTools Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $91.01M, a 14.42% decline from fiscal 2023.
- Standard BioTools Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $106.34M, a 8.57% increase from fiscal 2022.
- Standard BioTools Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $97.95M, a 24.99% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $20.10M 10-Q · filed 2026-08-05 | $41.25M 10-Q · filed 2026-08-05 | $65.05M derived: sum of 3 quarters · filed 2026-08-05 | $84.60M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $21.15M 10-Q · filed 2026-05-06 | $44.94M derived: sum of 2 quarters · filed 2026-05-06 | $64.49M derived: sum of 3 quarters · filed 2026-05-06 | $86.25M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $23.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $43.35M derived: sum of 2 quarters · filed 2026-03-16 | $65.11M derived: sum of 3 quarters · filed 2026-08-05 | $85.33M 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | $19.55M 10-Q · filed 2025-11-04 | $41.31M derived: sum of 2 quarters · filed 2026-08-05 | $61.54M 10-Q · filed 2025-11-04 | $86.31M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $21.76M 10-Q · filed 2026-08-05 | $41.98M 10-Q · filed 2026-08-05 | $66.76M derived: sum of 3 quarters · filed 2026-08-05 | $88.85M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $20.22M 10-Q · filed 2026-05-06 | $40.80M 10-Q · filed 2025-05-06 | $45.00M derived: sum of 2 quarters · filed 2026-05-06 | $67.08M derived: sum of 3 quarters · filed 2026-05-06 | $89.58M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $24.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $46.86M derived: sum of 2 quarters · filed 2026-03-16 | $69.36M derived: sum of 3 quarters · filed 2026-03-16 | $91.01M 10-K · filed 2026-03-16 | $174.43M 10-K · filed 2025-03-11 | |||
| 2024-09-30 | $22.09M 10-Q · filed 2025-11-04 | $44.97M 10-Q · filed 2024-11-06 | $44.58M derived: sum of 2 quarters · filed 2025-11-04 | $66.23M 10-Q · filed 2025-11-04 | $127.71M 10-Q · filed 2024-11-06 | $118.31M derived: sum of 4 quarters · filed 2026-03-16 | ||
| 2024-06-30 | $22.49M 10-Q · filed 2025-08-15 | $37.20M 10-Q · filed 2024-08-06 | $44.15M 10-Q · filed 2025-08-15 | $82.75M 10-Q · filed 2024-08-06 | $96.22M derived: sum of 3 quarters · filed 2026-03-16 | $121.59M derived: sum of 4 quarters · filed 2026-03-16 | ||
| 2024-03-31 | $45.54M 10-Q · filed 2025-05-06 | $73.73M derived: sum of 2 quarters · filed 2026-03-16 | $99.09M derived: sum of 3 quarters · filed 2026-03-16 | $126.76M derived: sum of 4 quarters · filed 2026-03-16 | ||||
| 2023-12-31 | $28.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $53.55M derived: sum of 2 quarters · filed 2026-03-16 | $81.22M derived: sum of 3 quarters · filed 2026-03-16 | $106.34M 10-K · filed 2026-03-16 | ||||
| 2023-09-30 | $25.37M 10-Q · filed 2024-11-06 | $53.03M derived: sum of 2 quarters · filed 2024-11-06 | $78.15M 10-Q · filed 2024-11-06 | $105.17M derived: sum of 4 quarters · filed 2025-03-11 | ||||
| 2023-06-30 | $27.67M 10-Q · filed 2024-08-06 | $52.78M 10-Q · filed 2024-08-06 | $79.81M derived: sum of 3 quarters · filed 2025-03-11 | $105.45M derived: sum of 4 quarters · filed 2025-03-11 | ||||
| 2023-03-31 | $25.12M 10-Q · filed 2024-05-09 | $52.14M derived: sum of 2 quarters · filed 2025-03-11 | $77.79M derived: sum of 3 quarters · filed 2025-03-11 | $96.56M derived: sum of 4 quarters · filed 2025-03-11 | ||||
| 2022-12-31 | $27.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $52.67M derived: sum of 2 quarters · filed 2025-03-11 | $71.44M derived: sum of 3 quarters · filed 2025-03-11 | $97.95M 10-K · filed 2025-03-11 | ||||
| 2022-09-30 | $25.65M 10-Q · filed 2023-11-07 | $44.42M derived: sum of 2 quarters · filed 2023-11-07 | $70.93M 10-Q · filed 2023-11-07 | $109.19M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | $18.78M 10-Q · filed 2023-08-08 | $45.28M 10-Q · filed 2023-08-08 | $83.55M derived: sum of 3 quarters · filed 2023-08-08 | $112.05M derived: sum of 4 quarters · filed 2023-08-08 | ||||
| 2022-03-31 | $26.50M 10-Q · filed 2023-05-09 | $64.77M derived: sum of 2 quarters · filed 2023-05-09 | $93.27M derived: sum of 3 quarters · filed 2023-05-09 | $124.29M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $38.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $66.77M derived: sum of 2 quarters · filed 2023-03-14 | $97.79M derived: sum of 3 quarters · filed 2023-03-14 | $130.58M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | $28.50M 10-Q · filed 2022-11-09 | $59.52M derived: sum of 2 quarters · filed 2022-11-09 | $92.32M 10-Q · filed 2022-11-09 | $136.92M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $31.02M 10-Q · filed 2022-08-09 | $63.81M 10-Q · filed 2022-08-09 | $108.42M derived: sum of 3 quarters · filed 2022-08-09 | $148.28M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | $32.79M 10-Q · filed 2022-05-09 | $77.40M derived: sum of 2 quarters · filed 2022-05-09 | $117.26M derived: sum of 3 quarters · filed 2022-05-09 | $143.32M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $44.61M 10-K · filed 2021-02-25 | $84.47M derived: sum of 2 quarters · filed 2021-11-09 | $110.53M derived: sum of 3 quarters · filed 2021-11-09 | $138.14M 10-K · filed 2022-03-08 | ||||
| 2020-09-30 | $39.86M 10-Q · filed 2021-11-09 | $65.92M derived: sum of 2 quarters · filed 2021-11-09 | $93.54M 10-Q · filed 2021-11-09 | $125.98M derived: sum of 4 quarters · filed 2021-11-09 | ||||
| 2020-06-30 | $26.06M 10-Q · filed 2021-08-06 | $53.67M 10-Q · filed 2021-08-06 | $86.11M derived: sum of 3 quarters · filed 2021-08-06 | $112.61M derived: sum of 4 quarters · filed 2021-08-06 | ||||
| 2020-03-31 | $27.62M 10-Q · filed 2021-05-07 | $60.06M derived: sum of 2 quarters · filed 2021-05-07 | $86.55M derived: sum of 3 quarters · filed 2021-05-07 | $114.75M derived: sum of 4 quarters · filed 2021-05-07 | ||||
| 2019-12-31 | $32.44M 10-K · filed 2021-02-25 | $58.94M derived: sum of 2 quarters · filed 2021-02-25 | $87.13M derived: sum of 3 quarters · filed 2021-02-25 | $117.24M 10-K · filed 2022-03-08 | ||||
| 2019-09-30 | $26.50M 10-K · filed 2021-02-25 | $54.69M derived: sum of 2 quarters · filed 2021-02-25 | $84.80M 10-Q · filed 2020-11-09 | $117.13M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $28.20M 10-K · filed 2021-02-25 | $58.31M 10-Q · filed 2020-08-07 | $90.63M derived: sum of 3 quarters · filed 2021-02-25 | $119.59M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $30.11M 10-K · filed 2021-02-25 | $62.44M derived: sum of 2 quarters · filed 2021-02-25 | $91.40M derived: sum of 3 quarters · filed 2021-02-25 | $117.83M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $32.33M 10-K · filed 2020-02-27 | $61.29M derived: sum of 2 quarters · filed 2020-02-27 | $87.72M derived: sum of 3 quarters · filed 2020-02-27 | $112.96M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $28.96M 10-K · filed 2020-02-27 | $55.39M derived: sum of 2 quarters · filed 2020-02-27 | $80.64M 10-Q · filed 2019-11-08 | $108.38M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-06-30 | $26.43M 10-K · filed 2020-02-27 | $51.68M 10-Q · filed 2019-08-07 | $79.42M derived: sum of 3 quarters · filed 2020-02-27 | $104.17M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | $25.25M 10-K · filed 2020-02-27 | $52.99M derived: sum of 2 quarters · filed 2020-02-27 | $77.74M derived: sum of 3 quarters · filed 2020-02-27 | $101.65M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | $27.75M 10-K · filed 2019-03-18 | $52.49M derived: sum of 2 quarters · filed 2019-03-18 | $76.40M derived: sum of 3 quarters · filed 2019-03-18 | $101.94M 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | $24.75M 10-K · filed 2019-03-18 | $48.66M derived: sum of 2 quarters · filed 2019-03-18 | $74.19M 10-Q · filed 2018-11-06 | |||||
| 2017-06-30 | $23.91M 10-K · filed 2019-03-18 | $49.45M 10-Q · filed 2018-08-08 | ||||||
| 2017-03-31 | $25.53M 10-K · filed 2019-03-18 | |||||||
| 2016-12-31 | $104.45M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |